LumiraDx Reports Third Quarter 2021 Financial Results

Rhea-AI Summary

LumiraDx (LMDX) announced its Q3 2021 financial results, reporting revenue of $109.1 million, significantly up from $13.9 million in Q3 2020. For the first nine months of 2021, revenue reached $303.2 million, compared to $26.9 million last year. The company expects full-year revenue to align with the consensus estimate of $367 million. Despite a gross margin of 36%, it faced challenges due to non-recurring production costs. Net income was reported at $84.8 million, equating to $0.46 per diluted share, influenced by accounting gains from a merger transaction.

Positive

• Revenue of $109.1 million for Q3 2021, up from $13.9 million in Q3 2020.
• Total revenue for nine months of 2021 at $303.2 million, significantly higher than $26.9 million in the same period last year.
• Full-year revenue guidance of around $367 million aligns with analyst consensus.
• Gross margin for Q3 2021 at 36%, indicating robust performance.
• Shipped over 19,300 Platforms, indicating strong market traction.

Negative

• Net loss of $29.8 million (or $0.16 per share) when adjusting for merger-related expenses.
• Gross margin negatively impacted by non-recurring costs associated with production ramp-up.
• SG&A expenses for Q3 2021 increased to $58.9 million, reflecting higher operational costs.

LONDON, Nov. 10, 2021 /PRNewswire/ -- LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for the quarter ended September 30, 2021.

• Revenue of $109.1M for the three months ended Sept. 30, 2021 and $303.2M for the nine months ended Sept. 30, 2021 rose significantly over revenue of $139.2M for the twelve months ended Dec. 31, 2020 on strong traction for our long-term strategy
• Platform revenue driven by higher COVID testing rates in all markets, especially U.S.; uptick in Europe for COVID Ag Pool tests enabling high throughput screening
• Fast Lab Solutions doubled its business enabling fast, accurate testing for laboratory customers
• Positive market development for INR tests for monitoring patients on oral anticoagulation therapy and D-Dimer for diagnosing deep vein thrombosis and pulmonary embolism
• Steady progress expanding geographies and testing menu for 30+ common health conditions in our planned pipeline

"LumiraDx's disruptive next-generation platform is just beginning to drive the transformation of community-based testing," said Chairman and CEO Ron Zwanziger: "Our first financial results as a public company demonstrate LumiraDx's tremendous growth potential driven by the need for fast, accurate and comprehensive diagnostic information to healthcare providers at the point of need. Our five platform tests in the market are delivering strong performance and we continue to make progress to expand our testing menu for diagnosing common conditions and improving health outcomes around the world."

2021 Third Quarter and First Nine Months Financial Highlights

For the first nine months of 2021, LumiraDx delivered $303.2 million in revenue compared to $26.9 million for the same period last year and $139.2 million for full year 2020. The company currently expects full year revenue for 2021 to be substantially in line with the average consensus analyst estimate of $367 million.   

The pandemic accelerated the company's vision to transform point-of-care diagnostics, enabling more than 19,300 Platforms shipped to customers as of the end of September 2021.  

For the third quarter of 2021, LumiraDx reported $109.1 million in revenue compared to $13.9 million for the same period last year. Covid Ag test strips accounted for $92.0 million of revenue in the third quarter of 2021 driven by higher testing rates in all markets, while Fast Lab Solutions delivered revenue of $10.3 million as adoption of our unique molecular chemistry has been accelerating.

Gross margin for the third quarter of 2021 was 36% and gross margin for the nine months ended September 30, 2021 was 32%. Margins were negatively impacted by non-recurring costs related to our rapid increase in production capacity and capabilities.

Research and development costs were $35.4 million in the third quarter of 2021. This represents an increase of 27% over the third quarter in 2020 as we continued to increase capabilities, opened our new R&D center in Glasgow and further resourced our development teams for continued pipeline delivery. 

SG&A expenses for the third quarter of 2021 of $58.9 million includes an IFRS 2 charge of $22.2 million for the difference in the fair value of the shares deemed to have been issued by LumiraDx in the merger transaction to CA Healthcare shareholders and the net assets of CA Healthcare and $8.6 million of LumiraDx transaction costs as part of LumiraDx's transaction to go public on Nasdaq. Excluding these items, SG&A expenses were $28.1 million, an increase of $15.9 million from the third quarter in 2020 as we expanded staffing globally to support the commercial growth of LumiraDx's Platform and Fast Lab Solutions.

Net income for the third quarter of 2021 was $84.8 million, or $0.46 per fully diluted share.  Net income arose from certain accounting gains on the conversion of our debt and equity securities as part of the merger transaction. Our non-IFRS adjusted net loss for the period, excluding merger expenses and excluding amortization, share-based payment expenses and unrealized foreign exchange gains was $29.8 million, or a loss of $0.16 per share.

At September 30, 2021, LumiraDx had $300 million in senior debt and $18 million in other term debt. The company's cash balance at September 30, 2021 was $217.7 million.

Conference Call

LumiraDx's senior management team will host a conference call today at 8:00 AM ET to discuss the company's financial results and business updates. Call in details and a link to view the webcast may be found at https://investors.lumiradx.com/news-and-events/investor-calendar.  A replay of the webcast will be available on the Investor's section of the company's website at investors.lumiradx.com shortly after the conclusion of the call. The webcast will be archived for 90 days.

About LumiraDx

LumiraDx (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Founded in 2014, LumiraDx manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. LumiraDx diagnostic testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease. LumiraDx has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform. In addition, LumiraDx has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need.
LumiraDx is based in the UK with more than 1500 employees worldwide.

Further information on LumiraDx and the LumiraDx Platform is available at www.lumiradx.com

Contact:
Colleen McMillen
Colleen.McMillen@lumiradx.com 
+1.917.344.9360

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the effectiveness of our strategy, regulatory progress and the advancement of our pipeline of tests, and the benefits and performance of our tests. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including, among others, general economic, political and business conditions; the effect of COVID-19 on LumiraDx's business and financial results; obtaining or maintaining regulatory approval, authorization or clearance for our tests; and those factors discussed under the header "Risk Factors" in the Proxy Statement and Prospectus filed pursuant to Rule 424B(3) with the Securities and Exchange Commission, or SEC on September 10, 2021 and other filings with the SEC. Although LumiraDx believes that it has a reasonable basis for each forward-looking statement contained in this press release, LumiraDx cautions you that these statements are based on a combination of facts and factors currently known by it and its projections of the future, about which it cannot be certain. LumiraDx undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Non-IFRS Financial Measures

We present non-IFRS financial measures because we believe that they and other similar measures are widely used by certain investors, securities analysts and other interested parties as supplemental measures of performance and liquidity. We also use these measures internally to establish forecasts, budgets and operational goals to manage and monitor our business, as well as evaluate our underlying historical performance, as we believe that these non-IFRS financial measures depict the true performance of the business by encompassing only relevant and controllable events, enabling us to evaluate and plan more effectively for the future. The non-IFRS financial measures may not be comparable to other similarly titled measures of other companies and have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of our operating results as reported under IFRS as issued by the IASB. Non-IFRS financial measures and margins are not measurements of our performance, financial condition or liquidity under IFRS as issued by the IASB and should not be considered as alternatives to [operating loss, gross margin or net income (loss)] or any other performance measures, derived in accordance with IFRS as issued by the IASB or any other generally accepted accounting principles.

We define non-IFRS operating loss and non-IFRS net income (loss) as operating loss and net income (loss), respectively, excluding amortization, share-based payments, IFRS 2 listing expense, change in fair value of financial instruments, foreign exchange (gain)/loss, dividends on preferred shares and non-cash interest.  We recommend that you review the reconciliation of the non-IFRS measure to the most directly comparable IFRS financial measure provided in the financial statement tables included below, and that you not rely on any single financial measure to evaluate our business.

LUMIRADX LIMITED
Unaudited Consolidated Statement of Financial Position
	DECEMBER 31, 2020				SEPTEMBER 30, 2021
	(in thousands, except share data)
ASSETS
Non–Current Assets
Other non-current assets	$	241			$	545
Intangibles and goodwill		40,723				38,208
Right-of-Use Assets		10,386				15,258
Property, plant and equipment		87,082				155,084
Total Non-Current Assets		138,432				209,095
Current Assets
Inventories		85,516				178,163
Tax receivable		20,680				13,281
Trade and other receivables		109,295				93,133
Restricted Cash		2,455				2,442
Cash and cash equivalents		158,717				215,285
Total Current Assets		376,663				502,304
TOTAL ASSETS	$	515,095			$	711,399
LIABILITIES AND EQUITY
Liabilities
Non-Current Liabilities
Debt due after more than one year	$	(139,734)			$	(308,399)
Preferred shares		(451,721)				-
Lease liabilities		(8,991)				(13,432)
Warrant liability		-				(6,690)
Deferred tax liabilities		(1,230)				(910)
Total Non-Current Liabilities		(601,676)				(329,431)
Current Liabilities
Debt due within one year		(147,238)				(557)
Trade and other payables		(138,783)				(191,143)
Lease liabilities due within one year		(2,114)				(4,874)
Total Current Liabilities		(288,135)				(196,574)
Equity
Share capital and share premium		(152,732)				(769,217)
Foreign currency translation reserve		19,905				17,532
Other reserves		(99,821)				(123,383)
Accumulated deficit		607,157				690,211
Total equity attributable to equity holders of the parent		374,509				(184,857)
Non-controlling interests		207				(537)
Total Equity		374,716				(185,394)
TOTAL EQUITY AND LIABILITIES	$	(515,095)			$	(711,399)

 

LUMIRADX LIMITED
Unaudited Consolidated Statement of Profit and Loss and Comprehensive Income
	THREE MONTHS ENDED SEPTEMBER 30,								NINE MONTHS ENDED SEPTEMBER 30,
	2021				2020				2021				2020
	(in thousands, except share and per share data)
Revenue
Products	$	108,131			$	12,688			$	300,064			$	23,318
Services		950				1,240				3,111				3,560
Total Revenue		109,081				13,928				303,175				26,878
Cost of sales
Products		70,066				12,397				205,326				18,915
Services		175				482				829				1,425
Total Cost of Sales		70,241				12,879				206,155				20,340
Gross Profit		38,840				1,049				97,020				6,538
Gross Profit Margin		36	%			8	%			32	%			24	%
Research and development expenses		35,396				27,919				96,399				79,843
Selling, marketing and administrative expenses		58,920				12,227				123,918				30,314
Operating Loss		(55,476)				(39,097)				(123,297)				(103,619)
Finance income		178,832				264				118,610				774
Finance expense		(37,589)				(27,970)				(103,949)				(75,596)
Net finance expense		141,243				(27,706)				14,661				(74,822)
Gain/(Loss) before Tax		85,767				(66,803)				(108,636)				(178,441)
Tax (provision)/credit for the period		(994)				4,473				(2,551)				9,143
Gain/(Loss) for the period	$	84,773			$	(62,330)			$	(111,187)			$	(169,298)
Loss attributable to non-controlling interest		34				36				322				(213)
Net gain/(loss) attributable to equity holders of parent—basic and diluted	$	84,739			$	(62,366)			$	(111,509)			$	(169,085)
Net gain/(loss) per share attributable to equity holders of parent—basic	$	0.63			$	(0.47)			$	(0.84)			$	(1.28)
Net gain/(loss) per share attributable to equity holders of parent—diluted	$	0.46			$	(0.47)			$	(0.84)			$	(1.28)
Weighted-average number of Ordinary Shares used in loss per share—basic		135,546,183				132,191,196				132,649,878				132,192,865
Weighted-average number of Ordinary Shares used in loss per share—diluted		183,227,228				132,191,196				132,649,878				132,192,865

 

LUMIRADX LIMITED
Unaudited Consolidated Statement of Cash Flows
	THREE MONTHS ENDED SEPTEMBER 30,								NINE MONTHS ENDED SEPTEMBER 30,
	2021				2020				2021				2020
	(in thousands, except share and per share data)
Cash Flows from Operating Activities
Income/(Loss) for the period	$	84,773			$	(62,330)			$	(111,187)			$	(169,298)
Adjustments to reconcile loss for the period to net cash used in operating activities:
Depreciation		7,134				1,948				14,673				4,935
Amortization		587				589				1,755				1,750
Net finance (income)/expenses		(146,807)				22,261				(30,748)				58,607
Share based payment expense		4,096				696				29,377				2,265
Increase in tax receivable		(1,466)				(4,666)				(2,839)				(9,208)
Accrued preferred shares dividends		5,445				5,445				16,156				16,215
IFRS 2 charge for difference in fair value of shares deemed issued		22,214				-				22,214				-
Changes to working capital:
Inventories		(4,188)				(20,531)				(92,995)				(31,824)
Trade and other receivables		(26,093)				(18,477)				27,526				(12,534)
Trade payables and other liabilities		29,825				8,294				43,688				14,426
Net Cash used in Operating Activities		(24,480)				(66,771)				(82,380)				(124,666)
Cash Flows from Investing Activities
Purchases of property, plant, equipment		(19,678)				(9,120)				(81,419)				(35,655)
Purchases of intangible assets		-				(23)				-				(45)
Cash paid for business investments		-				-				(1,968)				-
Cash received from merger		38,244				-				38,244				-
Net Cash generated from/(used in) Investing Activities		18,566				(9,143)				(45,143)				(35,700)
Cash Flows from Financing Activities
Proceeds from issuance of convertible notes, net of issuance costs		-				70,917				-				70,917
Proceeds from debt issuance, net of issuance costs		-				-				361,729				-
Proceeds from shares issued on the exercise of share options		-				15				-				15
Repayment of principal portion of lease liabilities		(2,572)				(925)				(4,830)				(2,028)
Cash interest paid, net of interest received		(9,035)				(4,026)				(23,662)				(7,894)
Fee on early extinguishment of debt		(37)				-				(2,387)				-
Repayments of debt		(66)				(52)				(140,286)				(244)
Net Cash (used in)/generated from Financing Activities		(11,710)				65,929				190,564				60,766
Net (Decrease)/Increase in Cash and Cash Equivalents		(17,624)				(9,985)				63,041				(99,600)
Movement in Cash and Cash Equivalents
Cash and cash equivalents at the beginning of the period		246,455				47,013				161,172				139,387
Exchange gain/(loss) on cash and cash equivalents		(11,104)				521				(6,486)				(2,238)
Net increase/(decrease) in cash and cash equivalents		(17,624)				(9,985)				63,041				(99,600)
Cash and Cash Equivalents at the end of the period	$	217,727			$	37,549			$	217,727			$	37,549

 

LUMIRADX LIMITED
Reconciliation of IFRS Financial Measures to Non-IFRS Financial Measures
	THREE MONTHS ENDED SEPTEMBER 30,
	Operating Loss								Net Income/(Loss)								Diluted EPS
	2021				2020				2021				2020				2021				2020
	(in thousands except share and per share data)
IFRS Financial Measure	$	(55,476)			$	(39,097)			$	84,773			$	(62,330)			$	0.46			$	(0.47)
Amortization		717				609				717				609				-				-
Share-based payments		4,097				784				4,097				784				0.02				0.01
SPAC merger transaction costs1		30,809				-				30,809				-				0.17				-
Change in fair value of financial instruments		-				-				(162,317)				29,740				(0.88)				0.22
Foreign exchange (gain)/loss		-				-				18,095				(15,198)				0.10				(0.11)
Dividends on preferred shares		-				-				(61,002)				5,445				(0.33)				0.04
Non-cash interest		-				-				55,009				3,877				0.30				0.03
Non-IFRS Adjusted Financial Measure	$	(19,853)			$	(37,704)			$	(29,819)			$	(37,073)			$	(0.16)			$	(0.28)
	NINE MONTHS ENDED SEPTEMBER 30,
	Operating Loss								Net Income/(Loss)								Diluted EPS
	2021				2020				2021				2020				2021				2020
	(in thousands except share and per share data)
IFRS Financial Measure	$	(123,297)			$	(103,619)			$	(111,187)			$	(169,298)			$	(0.84)			$	(1.28)
Amortization		1,885				1,769				1,885				1,769				0.02				0.01
Share-based payments		26,904				2,353				26,904				2,353				0.20				0.02
SPAC merger transaction costs1		30,809				-				30,809				-				0.23				-
Change in fair value of financial instruments		-				-				(102,065)				29,740				(0.77)				0.23
Foreign exchange (gain)/loss		-				-				13,267				11,058				0.10				0.08
Dividends on preferred shares		-				-				(50,291)				16,215				(0.38)				0.12
Non-cash interest		-				-				96,594				9,782				0.73				0.08
Non-IFRS Adjusted Financial Measure	$	(63,699)			$	(99,497)			$	(94,084)			$	(98,381)			$	(0.71)			$	(0.74)
1 - Includes an IFRS 2 charge of $22.2 million for the difference in the fair value of the shares deemed to have been issued by LumiraDx in the merger transaction to CA Healthcare shareholders and the net assets of CA Healthcare and $8.6 million of LumiraDx transaction costs.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lumiradx-reports-third-quarter-2021-financial-results-301420851.html

SOURCE LumiraDx

FAQ

What are LumiraDx's Q3 2021 financial results?

LumiraDx reported revenue of $109.1 million for Q3 2021, a significant increase from $13.9 million in Q3 2020.

What is LumiraDx's revenue expectation for the full year 2021?

LumiraDx expects full-year revenue to align with the consensus estimate of $367 million.

What was LumiraDx's net income for Q3 2021?

The net income for Q3 2021 was $84.8 million, which translates to $0.46 per diluted share.

How much revenue did LumiraDx generate in the first nine months of 2021?

In the first nine months of 2021, LumiraDx generated $303.2 million in revenue.

What challenges did LumiraDx face related to its margins?

LumiraDx's gross margin of 36% was negatively impacted by non-recurring costs due to the increase in production capacity.